Benign vena cava superior syndrome in patients with cardiac implantable electronic devices: Presentation and management

Eberhardt, Frank; Bunck, Alexander C.; Codjambopoulo, Phedon; Kalmbach, Kilian; Stöckigt, Florian

doi:10.1016/j.hrcr.2020.06.018

Cited by 3 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If symptoms are severe, catheterization is preferred for symptom improvement; Eberhardt et al performed vasodilation for SVC syndrome in a patient more than 10 years after pacemaker implantation and reported no problems after 1 year of treatment with rivaroxaban 20 mg ( 25 ). Pham also reported a case of balloon dilation for SVC obstruction and insertion of a new lead in a patient with SVC occlusion after 5 years ( 26 ).…”

Section: Therapeutic Strategy For Svc Obstruction After Lead Implanta...mentioning

confidence: 99%

Superior vena cava obstruction and cardiovascular implantable electronic devices—a new era of leadless devices

Kabutoya

2024

Mediastinum

View full text Add to dashboard Cite

Cardiovascular implantable electronic devices (CIEDs) such as pacemakers and implantable cardioverter defibrillators require the placement of a transvenous lead through the superior vena cava (SVC), which can be difficult if there is stenosis or obstruction of the SVC. Moreover, SVC syndrome may occur after the lead is inserted even if the SVC was intact before the implantation. Therefore, there is need of an appropriate strategy for handling stenosis or obstruction of SVC during lead placement. In addition, advances are being made in CIEDs that do not require transvenous leads, and thus CIEDs without a transvenous lead should be considered depending on the indications and urgency of the particular case. This manuscript is divided into (I) device therapy for patients with SVC obstruction and (II) therapeutic strategy for SVC obstruction after lead implantation. In patients with SVC syndrome, treatment of the SVC occlusion should be based on the individual pathophysiology, and depending on the indications and urgency of the case, treatment with CIEDs that do not require transvenous leads should be considered. Further data must be accumulated to clarify the long-term prognosis of device implantation after treatment of SVC occlusion. In addition, transvenous lead extraction is now widely used for device-related SVC obstruction, and this procedure also merits further accumulation of data.

show abstract

Section: Therapeutic Strategy For Svc Obstruction After Lead Implanta...mentioning

confidence: 99%

Superior vena cava obstruction and cardiovascular implantable electronic devices—a new era of leadless devices

Kabutoya

2024

Mediastinum

View full text Add to dashboard Cite

show abstract

“…Частота развития синдрома (СВПВ) верхней полой вены (ВПВ) составляет 0,005% от общей популяции населения и в большинстве случаев (до 70%) является осложнением прогрессирования злокачественного новообразования [1]. Однако увеличения количества имплантаций внутрисосудистых устройств различного применения привело к увеличению случаев развития доброкачественных форм СВПВ [2].…”

Section: Introductionunclassified

Endovascular treatment of lead-related superior vena cava syndrome after pacemaker implantation

Feshchenko,

Kaperiz,

Rudenko

et al. 2024

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Superior vena cava syndrome (SVCS) is due to impaired venous outflow from the head, neck, limbs and upper half of the body into the right atrium due to stenosis or complete obstruction of the superior vena cava (SVC). Increased venous pressure in the SVC and lack of timely treatment leads not only to serious complications, but also to death. In recent years, the etiology of SVCS has changed dramatically, mainly due to an increase in the number of implanted intravascular devices (central venous catheters, pacemakers, defibrillators, and other devices). Endovascular methods have become widely used in the treatment of patients with SVCS. This was primarily due to the minimally invasive nature of the intervention, the high technical success of the operation and the rapid onset of clinical improvement. Patients who develop SVCS after device implantation are predominantly younger and have a longer life expectancy. When choosing a treatment method, it is extremely important to take these factors into account and give preference to methods providing a long-term effect with the fewest possible complications. The article presents a case of endovascular treatment of a patient with SVCS occlusion, which developed 9 years after pacemaker implantation, using intravascular imaging methods.

show abstract

“…Superior vena cava (SVC) syndrome is a rare complication associated with transvenous cardiac implantable electronic devices that may present with a variety of manifestations, including facial plethora as well as more atypical symptoms such as subcutaneous thoracic congestion and ecchymoses from the recruitment of collateral circulation. 1 The earliest case reports of SVC syndrome date back to the 18 th century and describe infectious etiologies such as tuberculous lymphadenitis and syphilitic aortitis causing external compression of the SVC. 2 From the late 18 th century onward, malignancies-specifically lung cancer and non-Hodgkin's lymphoma-are the most common etiologies of SVC syndrome.…”

Section: Introductionmentioning

confidence: 99%

Lead-associated Superior Vena Cava Syndrome

Locke

Shim

Burr

et al. 2021

J Innov Cardiac Rhythm Manage.

View full text Add to dashboard Cite

Superior vena cava (SVC) syndrome is a rare complication associated with transvenous cardiac implantable electronic devices that may present with a variety of manifestations. Various strategies such as transvenous lead extraction, anticoagulation, venoplasty, and stenting have been used to treat this condition, but the optimal management protocols have yet to be defined. Subcutaneous implantable cardioverter-defibrillator (ICD) (S-ICD) therapy can be an alternative option to a transvenous system for those who require future ICD surveillance. We present a case of lead-associated SVC syndrome where thoracic venous congestion due to SVC obstruction influenced preimplant S-ICD QRS vector screening. Following treatment of venous obstruction, QRS amplitude may change and patients who were not initially S-ICD candidates may later become eligible.

show abstract

Benign vena cava superior syndrome in patients with cardiac implantable electronic devices: Presentation and management

Cited by 3 publications

References 11 publications

Superior vena cava obstruction and cardiovascular implantable electronic devices—a new era of leadless devices

Superior vena cava obstruction and cardiovascular implantable electronic devices—a new era of leadless devices

Endovascular treatment of lead-related superior vena cava syndrome after pacemaker implantation

Lead-associated Superior Vena Cava Syndrome

Contact Info

Product

Resources

About